<?xml version="1.0" encoding="UTF-8"?>
<p>Antiobesity treatment protocols recommend the regulation of food intake and also intake agents which affect the absorption of dietary fat, metabolism, and storage of fats [
 <xref rid="B31" ref-type="bibr">31</xref>]. Orlistat is a potent inhibitor of gastric and pancreatic lipase, which is a hydrogenated derivative of lipstatin, produced by 
 <italic>Streptomyces toxytricini</italic> and acts by diminishing the absorption of dietary fat. Orlistat forms a covalent bond with the active serine site of lipases and thus inactivates them to hydrolyze dietary fat. It has several side effects including flatulence, incontinence, fecal urgency, fat-soluble vitamin deficiencies, abdominal cramping, steatorrhea, and liquid stools [
 <xref rid="B32" ref-type="bibr">32</xref>].
</p>
